|
| Primary information |
|---|
| ID | 10834 |
| Therapeutic ID | Th1200 |
| Protein Name | Prothrombin complex concentrate |
| Sequence | NA
|
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | Factor II - 48-60 hrs; factor VII - 1.5-6 hrs; factor IX - 20-24 hrs and factor X - 24 - 48 hrs. |
| Description | Anti-inhibitor coagulant complex, also known as activated prothrombin complex concentrate (APCC) is a preparation containing precursor and activated forms of blood coagulation factors II, VII, IX, and X derived from pooled human venous plasma. |
| Indication/Disease | For use in hemophilia A and B patients with inhibitors for: 1) control and prevention of bleeding episodes; 2) perioperative management; and 3) Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. |
| Pharmacodynamics | The administration of human prothrombin complex provides an increase in plasma levels of the vitamin K dependent coagulation factors, and can temporarily correct the coagulation defect of patients with deficiency of one or several of these factors. |
| Mechanism of Action | They act by reversal of anticoagulants |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| NA |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Brand Name | Feiba Nf |
| Company | Baxter Healthcare Corporation |
| Brand Description | Baxter Healthcare Corporation |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | Freeze-dried fraction |
| Route of Administration | Intravenous |
| Recommended Dosage | Do not exceed a single dose of 100 units per kg body weight and a daily dose of 200 units per kg body |
| Contraindication | Known anaphylactic or severe hypersensitivity reactions to FEIBA or any if its components, including factors of the kinin generating system. Disseminated intravascular coagulation (DIC). Acute thrombosis or embolism (including myocardial infarction). |
| Side Effects | The most frequently reported adverse reactions observed in > 5% of subjects in the prophylaxis trial were anemia, diarrhea, hemarthrosis, hepatitis B surface antibody positive, nausea, and vomiting. The serious adverse reactions seen with FEIBA are hypersensitivity reactions and thromboembolic events, including stroke, pulmonary embolism and deep vein thrombosis. |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |